Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY.

Breast Cancer Res Treat. 2017 Aug;165(1):181-191. doi: 10.1007/s10549-017-4303-8. Epub 2017 Jun 2.

3.

Association between breast cancer genetic susceptibility variants and terminal duct lobular unit involution of the breast.

Bodelon C, Oh H, Chatterjee N, Garcia-Closas M, Palakal M, Sherman ME, Pfeiffer RM, Geller B, Vacek P, Weaver DL, Chicoine R, Papathomas D, Xiang J, Patel DA, Khodr ZG, Linville L, Clare SE, Visscher DW, Mies C, Hewitt SM, Brinton LA, Storniolo AMV, He C, Chanock SJ, Gierach GL, Figueroa JD.

Int J Cancer. 2017 Feb 15;140(4):825-832. doi: 10.1002/ijc.30512. Epub 2016 Nov 18.

4.

BIM facilities applications. Three areas that can benefit from building information modeling.

Mies CE, Mergenschroer M.

Health Facil Manage. 2016 Oct;29(10):30-3. No abstract available.

PMID:
29488738
5.

Ages at menarche- and menopause-related genetic variants in relation to terminal duct lobular unit involution in normal breast tissue.

Oh H, Bodelon C, Palakal M, Chatterjee N, Sherman ME, Linville L, Geller BM, Vacek PM, Weaver DL, Chicoine RE, Papathomas D, Patel DA, Xiang J, Clare SE, Visscher DW, Mies C, Hewitt SM, Brinton LA, Storniolo AM, He C, Garcia-Closas M, Chanock SJ, Gierach GL, Figueroa JD.

Breast Cancer Res Treat. 2016 Jul;158(2):341-50. doi: 10.1007/s10549-016-3859-z. Epub 2016 Jun 24.

6.

Lymph node content of supraclavicular and thoracodorsal-based axillary flaps for vascularized lymph node transfer.

Gerety PA, Pannucci CJ, Basta MN, Wang AR, Zhang P, Mies C, Kanchwala SK.

J Vasc Surg Venous Lymphat Disord. 2016 Jan;4(1):80-7. doi: 10.1016/j.jvsv.2015.06.004. Epub 2015 Sep 12.

PMID:
26946900
7.

Breast DCE-MRI Kinetic Heterogeneity Tumor Markers: Preliminary Associations With Neoadjuvant Chemotherapy Response.

Ashraf A, Gaonkar B, Mies C, DeMichele A, Rosen M, Davatzikos C, Kontos D.

Transl Oncol. 2015 Jun;8(3):154-62. doi: 10.1016/j.tranon.2015.03.005.

8.

Feasibility of the internal mammary lymph node flap as a vascularized lymph node transfer: A cadaveric dissection study.

Pannucci CJ, Gerety PA, Wang AR, Zhang P, Mies C, Kanchwala SK.

Microsurgery. 2016 Sep;36(6):485-90. doi: 10.1002/micr.22398. Epub 2015 Mar 6.

PMID:
25752677
9.

Pharmacokinetic Tumor Heterogeneity as a Prognostic Biomarker for Classifying Breast Cancer Recurrence Risk.

Mahrooghy M, Ashraf AB, Daye D, McDonald ES, Rosen M, Mies C, Feldman M, Kontos D.

IEEE Trans Biomed Eng. 2015 Jun;62(6):1585-94. doi: 10.1109/TBME.2015.2395812. Epub 2015 Jan 23.

PMID:
25622311
10.

Vascularized Lymph Node Transfer for Lymphedema: Anatomic Comparison of the Supraclavicular and Thoracodorsal Lymph Node Flaps.

Pannucci C, Gerety PA, Basta MN, Wang AR, Mies C, Zhang P, Kanchwala SK.

J Vasc Surg Venous Lymphat Disord. 2015 Jan;3(1):124. doi: 10.1016/j.jvsv.2014.10.023. Epub 2014 Dec 15. No abstract available.

PMID:
26993710
11.

Circulating sex hormones and terminal duct lobular unit involution of the normal breast.

Khodr ZG, Sherman ME, Pfeiffer RM, Gierach GL, Brinton LA, Falk RT, Patel DA, Linville LM, Papathomas D, Clare SE, Visscher DW, Mies C, Hewitt SM, Storniolo AM, Rosebrock A, Caban JJ, Figueroa JD.

Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2765-73. doi: 10.1158/1055-9965.EPI-14-0667.

12.

Terminal duct lobular unit involution of the normal breast: implications for breast cancer etiology.

Figueroa JD, Pfeiffer RM, Patel DA, Linville L, Brinton LA, Gierach GL, Yang XR, Papathomas D, Visscher D, Mies C, Degnim AC, Anderson WF, Hewitt S, Khodr ZG, Clare SE, Storniolo AM, Sherman ME.

J Natl Cancer Inst. 2014 Oct 1;106(10). pii: dju286. doi: 10.1093/jnci/dju286. Print 2014 Oct.

13.

Optically measured microvascular blood flow contrast of malignant breast tumors.

Choe R, Putt ME, Carlile PM, Durduran T, Giammarco JM, Busch DR, Jung KW, Czerniecki BJ, Tchou J, Feldman MD, Mies C, Rosen MA, Schnall MD, DeMichele A, Yodh AG.

PLoS One. 2014 Jun 26;9(6):e99683. doi: 10.1371/journal.pone.0099683. eCollection 2014.

14.

Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657).

Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A; I-SPY1 Investigators.

Cancer Med. 2014 Jun;3(3):693-701. doi: 10.1002/cam4.235. Epub 2014 Apr 9.

15.

Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression profiles.

Ashraf AB, Daye D, Gavenonis S, Mies C, Feldman M, Rosen M, Kontos D.

Radiology. 2014 Aug;272(2):374-84. doi: 10.1148/radiol.14131375. Epub 2014 Apr 4.

16.

Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced MR images: a feasibility study.

Agner SC, Rosen MA, Englander S, Tomaszewski JE, Feldman MD, Zhang P, Mies C, Schnall MD, Madabhushi A.

Radiology. 2014 Jul;272(1):91-9. doi: 10.1148/radiol.14121031. Epub 2014 Mar 10.

17.

Heterogeneity wavelet kinetics from DCE-MRI for classifying gene expression based breast cancer recurrence risk.

Mahrooghy M, Ashraf AB, Daye D, Mies C, Feldman M, Rosen M, Kontos D.

Med Image Comput Comput Assist Interv. 2013;16(Pt 2):295-302.

PMID:
24579153
18.
19.

Fibroblast activation protein expression by stromal cells and tumor-associated macrophages in human breast cancer.

Tchou J, Zhang PJ, Bi Y, Satija C, Marjumdar R, Stephen TL, Lo A, Chen H, Mies C, June CH, Conejo-Garcia J, Puré E.

Hum Pathol. 2013 Nov;44(11):2549-57. doi: 10.1016/j.humpath.2013.06.016. Epub 2013 Sep 26.

20.

Cutaneous metastatic breast carcinoma with clear cell features.

Shinohara MM, Tozbikian G, Wolfe JT, Shin SJ, Mies C, Elenitsas R.

J Cutan Pathol. 2013 Aug;40(8):753-7. doi: 10.1111/cup.12162. Epub 2013 May 14.

PMID:
23672673
21.

Multi-field-of-view framework for distinguishing tumor grade in ER+ breast cancer from entire histopathology slides.

Basavanhally A, Ganesan S, Feldman M, Shih N, Mies C, Tomaszewski J, Madabhushi A.

IEEE Trans Biomed Eng. 2013 Aug;60(8):2089-99. doi: 10.1109/TBME.2013.2245129. Epub 2013 Feb 5.

22.

Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy.

Busch DR, Choe R, Rosen MA, Guo W, Durduran T, Feldman MD, Mies C, Czerniecki BJ, Tchou J, Demichele A, Schnall MD, Yodh AG.

Biomed Opt Express. 2013 Jan 1;4(1):105-21. doi: 10.1364/BOE.4.000105. Epub 2012 Dec 14.

23.

A multichannel Markov random field framework for tumor segmentation with an application to classification of gene expression-based breast cancer recurrence risk.

Ashraf AB, Gavenonis SC, Daye D, Mies C, Rosen MA, Kontos D.

IEEE Trans Med Imaging. 2013 Apr;32(4):637-48. doi: 10.1109/TMI.2012.2219589. Epub 2012 Sep 19.

24.

Intraosseous hibernoma: a potential mimic of metastatic carcinoma.

Bai S, Mies C, Stephenson J, Zhang PJ.

Ann Diagn Pathol. 2013 Apr;17(2):204-6. doi: 10.1016/j.anndiagpath.2012.07.001. Epub 2012 Aug 11.

PMID:
22884657
25.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N.

J Clin Oncol. 2012 Sep 10;30(26):3242-9. doi: 10.1200/JCO.2011.39.2779. Epub 2012 May 29.

26.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25.

27.

A multichannel Markov random field approach for automated segmentation of breast cancer tumor in DCE-MRI data using kinetic observation model.

Ashraf AB, Gavenonis S, Daye D, Mies C, Feldman M, Rosen M, Kontos D.

Med Image Comput Comput Assist Interv. 2011;14(Pt 3):546-53.

PMID:
22003742
28.

Multi-field-of-view strategy for image-based outcome prediction of multi-parametric estrogen receptor-positive breast cancer histopathology: Comparison to Oncotype DX.

Basavanhally A, Feldman M, Shih N, Mies C, Tomaszewski J, Ganesan S, Madabhushi A.

J Pathol Inform. 2011;2:S1. doi: 10.4103/2153-3539.92027. Epub 2012 Jan 19.

29.

Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome.

Abramson VG, Troxel AB, Feldman M, Mies C, Wang Y, Sherman L, McNally S, Diehl A, Demichele A.

Anticancer Res. 2010 Apr;30(4):1279-85.

30.

Computer aided automatic detection of malignant lesions in diffuse optical mammography.

Busch DR, Guo W, Choe R, Durduran T, Feldman MD, Mies C, Rosen MA, Schnall MD, Czerniecki BJ, Tchou J, DeMichele A, Putt ME, Yodh AG.

Med Phys. 2010 Apr;37(4):1840-9.

31.

Massive hemorrhage and infarction complicating focal nodular hyperplasia of the liver.

Bathe OF, Mies C, Franceschi D, Casillas J, Livingstone AS.

HPB (Oxford). 2003;5(2):123-6. doi: 10.1080/13651820310013454.

32.

Application of immunohistochemistry to breast lesions.

Yeh IT, Mies C.

Arch Pathol Lab Med. 2008 Mar;132(3):349-58. doi: 10.1043/1543-2165(2008)132[349:AOITBL]2.0.CO;2. Review.

PMID:
18318578
33.

Assessing the significance of conserved genomic aberrations using high resolution genomic microarrays.

Guttman M, Mies C, Dudycz-Sulicz K, Diskin SJ, Baldwin DA, Stoeckert CJ Jr, Grant GR.

PLoS Genet. 2007 Aug;3(8):e143.

34.

Serum concentrations of estrogens, sex hormone-binding globulin, and androgens and risk of breast cancer in postmenopausal women.

Adly L, Hill D, Sherman ME, Sturgeon SR, Fears T, Mies C, Ziegler RG, Hoover RN, Schairer C.

Int J Cancer. 2006 Nov 15;119(10):2402-7.

35.

MR imaging-guided 9-gauge vacuum-assisted core-needle breast biopsy: initial experience.

Orel SG, Rosen M, Mies C, Schnall MD.

Radiology. 2006 Jan;238(1):54-61. Epub 2005 Nov 22.

PMID:
16304093
36.

Serum concentrations of estrogens, sex hormone binding globulin, and androgens and risk of breast hyperplasia in postmenopausal women.

Schairer C, Hill D, Sturgeon SR, Fears T, Mies C, Ziegler RG, Hoover RN, Sherman ME.

Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1660-5.

37.

Breast reconstruction with a transverse rectus abdominis myocutaneous flap: spectrum of normal and abnormal MR imaging findings.

Devon RK, Rosen MA, Mies C, Orel SG.

Radiographics. 2004 Sep-Oct;24(5):1287-99. Review.

PMID:
15371609
38.

Posterior acoustic shadowing in benign breast lesions: sonographic-pathologic correlation.

Weinstein SP, Conant EF, Mies C, Acs G, Lee S, Sehgal C.

J Ultrasound Med. 2004 Jan;23(1):73-83.

PMID:
14756356
39.

Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women.

Schairer C, Hill D, Sturgeon SR, Fears T, Pollak M, Mies C, Ziegler RG, Hoover RN, Sherman ME.

Int J Cancer. 2004 Feb 20;108(5):773-9.

40.

Gene-expression profiles and breast-cancer prognosis.

Master SR, Mies C.

Adv Anat Pathol. 2003 Nov;10(6):338-46. No abstract available.

PMID:
14581823
41.

The Cooperative Breast Cancer Tissue Resource: archival tissue for the investigation of tumor markers.

Glass AG, Donis-Keller H, Mies C, Russo J, Zehnbauer B, Taube S, Aamodt R; Cooperative Breast Cancer Tissue Resource.

Clin Cancer Res. 2001 Jul;7(7):1843-9.

42.

Stereotactic Core Biopsy of the Breast.

Mies C, Lentz JC, Moffat FL.

Breast J. 2000 May;6(3):197-198. No abstract available.

PMID:
11348364
43.

Genitourinary tuberculosis after renal transplantation: report of 3 cases and review.

Dowdy L, Ramgopal M, Hoffman T, Ciancio G, Burke G, Roth D, Mies C, Jones B, Miller J.

Clin Infect Dis. 2001 Feb 15;32(4):662-6. Epub 2001 Feb 7. Review.

PMID:
11181136
44.

Detection of "occult" lymph node metastasis in breast cancer: should pathologists go the extra mile?

Mies C, Schlesselman JJ.

Adv Anat Pathol. 2000 May;7(3):149-52.

PMID:
10809220
45.

Electronic cancer Munchausen syndrome.

Hadeed V, Trump DL, Mies C.

Ann Intern Med. 1998 Jul 1;129(1):73. No abstract available.

PMID:
9653009
46.

The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: a phase II trial of neoadjuvant MVAC, surgery, and radiation.

Abdel-Wahab M, Wolfson A, Raub W, Mies C, Brandon A, Morrell L, Lee Y, Ling S, Markoe A.

Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):875-80.

PMID:
9531373
47.

A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma.

Morrell LE, Lee YJ, Hurley J, Arias M, Mies C, Richman SP, Fernandez H, Donofrio KA, Raub WA Jr, Cassileth PA.

Cancer. 1998 Feb 1;82(3):503-11.

PMID:
9452268
48.

Discrimination of late apoptotic/necrotic cells (type III) by flow cytometry in solid tumors.

O'Brien MC, Healy SF Jr, Raney SR, Hurst JM, Avner B, Hanly A, Mies C, Freeman JW, Snow C, Koester SK, Bolton WE.

Cytometry. 1997 May 1;28(1):81-9.

PMID:
9136759
49.
50.

Sucrase-isomaltase is an independent prognostic marker for colorectal carcinoma.

Jessup JM, Lavin PT, Andrews CW Jr, Loda M, Mercurio A, Minsky BD, Mies C, Cukor B, Bleday R, Steele G Jr.

Dis Colon Rectum. 1995 Dec;38(12):1257-64.

PMID:
7497836

Supplemental Content

Support Center